Erudio Healtherudio.com
Drug
Lifileucel trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying lifileucel: SUPRAME. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 4 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| SUPRAME NCT06743126 · Immatics US, Inc. | previously treated, unresectable or metastatic cutaneous melanoma | Phase 3 | 108 | 39 | Focused | Nov 20, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| IOV-COM-202 NCT03645928 · Iovance Biotherapeutics, Inc. DeepView → | solid tumors | Phase 2 | Deep | View | |||
| IOV-SAR-201 NCT07741877 · Iovance Biotherapeutics, Inc. FocusedView → | previously treated advanced soft tissue sarcoma | Phase 2 | Focused | View | |||
| LN-144 NCT02360579 · Iovance Biotherapeutics, Inc. FocusedView → | metastatic melanoma | Phase 2 | Focused | View | |||
| NCT05607095 NCT05607095 · Memorial Sloan Kettering Cancer Center FocusedView → | Not given | Phase 1 | Focused | View | |||